N-[5-({3-[5-(Acetyl-hydroxy-amino)-pentylcarbamoyl]-propionyl}-hydroxy-amino)-pentyl]-N'-{5-[(hexahydro-2,5-methano-pentalene-3a-carbonyl)-amino]-pentyl}-N'-hydroxy-succinamide

ID: ALA4205505

Chembl Id: CHEMBL4205505

PubChem CID: 145975380

Max Phase: Preclinical

Molecular Formula: C35H60N6O9

Molecular Weight: 708.90

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)C12CC3CC(CC1C3)C2

Standard InChI:  InChI=1S/C35H60N6O9/c1-26(42)39(48)18-8-2-5-15-36-30(43)11-13-32(45)40(49)19-9-3-6-16-37-31(44)12-14-33(46)41(50)20-10-4-7-17-38-34(47)35-24-27-21-28(25-35)23-29(35)22-27/h27-29,48-50H,2-25H2,1H3,(H,36,43)(H,37,44)(H,38,47)

Standard InChI Key:  GZAPWVXIFQXYPW-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4205505

    ---

Associated Targets(Human)

SK-N-BE(2)-M17 (195 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Astrocyte (46 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 708.90Molecular Weight (Monoisotopic): 708.4422AlogP: 2.91#Rotatable Bonds: 25
Polar Surface Area: 208.92Molecular Species: NEUTRALHBA: 9HBD: 6
#RO5 Violations: 2HBA (Lipinski): 15HBD (Lipinski): 6#RO5 Violations (Lipinski): 3
CX Acidic pKa: 7.92CX Basic pKa: 0.23CX LogP: -0.04CX LogD: -0.17
Aromatic Rings: Heavy Atoms: 50QED Weighted: 0.05Np Likeness Score: 0.13

References

1. Telfer TJ, Liddell JR, Duncan C, White AR, Codd R..  (2017)  Adamantyl- and other polycyclic cage-based conjugates of desferrioxamine B (DFOB) for treating iron-mediated toxicity in cell models of Parkinson's disease.,  27  (8): [PMID:28285915] [10.1016/j.bmcl.2017.03.001]

Source